Journal of Kerman University of Medical Sciences

Evaluation of the Serum Levels of Osteopontin in Iranian Patients with Benign and Malignant Salivary Gland Tumors

Document Type : Original Article

Authors

Azadeh Andisheh Tadbir 1
Javad Moayedi 2
Maryam Jamilzadeh 3
Bijan Khademi 4
Mahyar Malekzadeh 4
Maryam Mardani 5

1 Oral and Dental Disease Research Center, Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Molecular Medicine, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran

3 Department of Oral and Maxillofacial Medicine, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran

4 Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

5 Oral and Dental Disease Research Center, Department of Oral and Maxillofacial Medicine, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran

https://doi.org/10.34172/jkmu.3766
Abstract
Background: Osteopontin (OPN) is a phosphorylated glycoprotein involved in a wide variety of biological functions including cancer pathogenesis and metastasis. However, its clinical value in salivary gland tumors (SGTs) has received little attention. Hence, this study aimed to investigate serum levels of OPN in Iranian patients with benign and malignant SGTs to explore its correlation with the clinicopathologic characteristics of patients.
Methods: This cross-sectional study was performed on 90 patients with SGTs including malignant (n=60) and benign (n=30) cases. Sixty age- and sex-matched healthy individuals were also considered as the control group. Serum levels of OPN in all samples were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit.
Results: The levels of OPN showed significant differences between the patient and control groups (23.16±11.08 ng/mL vs. 10.61±4.99 ng/mL, p<0.0001), as well as between malignant and benign cases of SGTs (26.64±11.73 ng/mL vs. 16.19±4.68 ng/mL, p<0.0001). Additionally, OPN concentration was significantly associated with clinicopathologic characteristics of patients including tumor size, tumor, node and metastasis (TNM) classification, and lymph node involvement, but not with patients' gender, age, size, and type of lesions.
Conclusion: Based on the findings, serum levels of OPN could be used as a supportive biomarker to diagnose SGTs and differentiate between benign and malignant cases. This is a preliminary study; therefore, further studies with larger sample sizes and longer follow-ups are highly warranted to assess the potential of OPN for the diagnosis of SGTs at earlier stages.

Highlights

Maryam Mardani (Google Scholar) (PubMed)

Keywords

Osteopontin
Salivary gland tumors
Clinicopathological characteristics
Subjects
  1. Wang X, Luo Y, Li M, Yan H, Sun M, Fan T. Management of salivary gland carcinomas - a review. Oncotarget. 2017;8(3):3946-56. doi: 10.18632/oncotarget.13952.
  2. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006;24(17):2673-8. doi: 10.1200/jco.2005.05.3025.
  3. Bialek EJ, Jakubowski W, Zajkowski P, Szopinski KT, Osmolski A. US of the major salivary glands: anatomy and spatial relationships, pathologic conditions, and pitfalls. Radiographics. 2006;26(3):745-63. doi: 10.1148/ rg.263055024.
  4. Shishegar M, Ashraf MJ, Azarpira N, Khademi B, Hashemi B, Ashrafi A. Salivary gland tumors in maxillofacial region: a retrospective study of 130 cases in a southern Iranian population. Patholog Res Int. 2011;2011:934350. doi: 10.4061/2011/934350.
  5. Copelli C, Bianchi B, Ferrari S, Ferri A, Sesenna E. Malignant tumors of intraoral minor salivary glands. Oral Oncol. 2008;44(7):658-63. doi: 10.1016/j.oraloncology.2007.08.018.
  6. Peravali RK, Bhat HH, Upadya VH, Agarwal A, Naag S. Salivary gland tumors: a diagnostic dilemma! J Maxillofac Oral Surg. 2015;14(Suppl 1):438-42. doi: 10.1007/s12663-014-0665-1.
  7. Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Keus RB, Hart AA. Stage as major long-term outcome predictor in minor salivary gland carcinoma. Cancer. 2000;89(6):1195- 204. doi: 10.1002/1097-0142(20000915)89:6 < 1195::aid-cncr2 > 3.3.co;2-a.
  8. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14(8):2037-44. doi: 10.1111/j.1582-4934.2010.01115.x.
  9. Moorman HR, Poschel D, Klement JD, Lu C, Redd PS, Liu K. Osteopontin: a key regulator of tumor progression and immunomodulation. Cancers (Basel). 2020;12(11):3379. doi: 10.3390/cancers12113379.
  10. Icer MA, Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clin Biochem. 2018;59:17-24. doi: 10.1016/j.clinbiochem.2018.07.003.
  11. Christensen B, Kläning E, Nielsen MS, Andersen MH, Sørensen ES. C-terminal modification of osteopontin inhibits interaction with the αVβ3-integrin. J Biol Chem. 2012;287(6):3788-97. doi: 10.1074/jbc.M111.277996.
  12. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes. J Cell Commun Signal. 2009;3(3- 4):311-22. doi: 10.1007/s12079-009-0068-0.
  13. Hao C, Cui Y, Owen S, Li W, Cheng S, Jiang WG. Human osteopontin: potential clinical applications in cancer. Int J Mol Med. 2017;39(6):1327-37. doi: 10.3892/ijmm.2017.2964.
  14. Moszynski R, Szubert S, Szpurek D, Michalak S, Sajdak S. Role of osteopontin in differential diagnosis of ovarian tumors. J Obstet Gynaecol Res. 2013;39(11):1518-25. doi: 10.1111/ jog.12097.
  15. Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, et al. Osteopontin at the crossroads of inflammation and tumor progression. Mediators Inflamm. 2017;2017:4049098. doi: 10.1155/2017/4049098.
  16. Yin M, Soikkeli J, Jahkola T, Virolainen S, Saksela O, Hölttä E. Osteopontin promotes the invasive growth of melanoma cells by activating integrin αvβ3 and down-regulating tetraspanin CD9. Am J Pathol. 2014;184(3):842-58. doi: 10.1016/j. ajpath.2013.11.020.
  17. Saup R, Nair N, Shen J, Schmaus A, Thiele W, Garvalov BK, et al. Increased circulating osteopontin levels promote primary tumour growth, but do not induce metastasis in melanoma. Biomedicines. 2023;11(4):1038. doi: 10.3390/ biomedicines11041038.
  18. Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, et al. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005;124(5):1044-52. doi: 10.1111/j.0022- 202X.2005.23680.x.
  19. Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, Vrinda M, et al. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev. 2010;19(6):1409-22. doi: 10.1158/1055-9965.Epi-09-1077.
  20. Yan W, Qian C, Zhao P, Zhang J, Shi L, Qian J, et al. Expression pattern of osteopontin splice variants and its functions on cell apoptosis and invasion in glioma cells. Neuro Oncol. 2010;12(8):765-75. doi: 10.1093/neuonc/noq006.
  21. Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis. 2018;9(3):356. doi: 10.1038/s41419-018-0391-6.
  22. Barak V, Meirovitz A, Leibovici V, Rachmut J, Peretz T, Eliashar R, et al. The diagnostic and prognostic value of tumor markers (CEA, SCC, CYFRA 21-1, TPS) in head and neck cancer patients. Anticancer Res. 2015;35(10):5519-24.
  23. Yuan C, Yang K, Tang H, Chen D. Diagnostic values of serum tumor markers Cyfra21-1, SCCAg, ferritin, CEA, CA19-9, and AFP in oral/oropharyngeal squamous cell carcinoma. Onco Targets Ther. 2016;9:3381-6. doi: 10.2147/ott.S105672.
  24. Darling MR, Gauthier M, Jackson-Boeters L, Daley TD, Chambers AF, Tuck AB. Osteopontin expression in salivary gland tumours. Oral Oncol. 2006;42(4):363-9. doi: 10.1016/j. oraloncology.2005.09.004.
  25. Brown LF, Berse B, Van de Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, et al. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell. 1992;3(10):1169- 80. doi: 10.1091/mbc.3.10.1169.
  26. Kusafuka K, Yamaguchi A, Kayano T, Takemura T. Expression of bone matrix proteins, osteonectin and osteopontin, in salivary pleomorphic adenomas. Pathol Res Pract. 1999;195(11):733- 9. doi: 10.1016/s0344-0338(99)80114-9.
  27. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004;10(1 Pt 1):184-90. doi: 10.1158/1078-0432.ccr-1405-2.
  28. Bjørndal K, Larsen SR, Godballe C, Krogdahl A. Osteopontin expression in salivary gland carcinomas. J Oral Pathol Med. 2011;40(6):451-5. doi: 10.1111/j.1600-0714.2010.00964.x.
  29. Fok TC, Lapointe H, Tuck AB, Chambers AF, Jackson-Boeters L, Daley TD, et al. Expression and localization of osteopontin, homing cell adhesion molecule/CD44, and integrin αvβ3 in mucoepidermoid carcinoma and acinic cell adenocarcinoma of salivary gland origin. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118(3):320-9. doi: 10.1016/j.oooo.2014.05.004.
  30. Forootan SS, Foster CS, Aachi VR, Adamson J, Smith PH, Lin K, et al. Prognostic significance of osteopontin expression in human prostate cancer. Int J Cancer. 2006;118(9):2255-61. doi: 10.1002/ijc.21619.
  31. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer. 2002;95(3):506-12. doi: 10.1002/cncr.10709.
  32. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003;98(1):119- 27. doi: 10.1002/cncr.11487.
  33. Wai PY, Kuo PC. The role of osteopontin in tumor metastasis. J Surg Res. 2004;121(2):228-41. doi: 10.1016/j. jss.2004.03.028.
  34. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56(6):782-9. doi: 10.1136/gut.2006.109868.
  35. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol. 2006;169(1):233-46. doi: 10.2353/ajpath.2006.051152.
  36. Cho H, Hong SW, Oh YJ, Kim MA, Kang ES, Lee JM, et al. Clinical significance of osteopontin expression in cervical cancer. J Cancer Res Clin Oncol. 2008;134(8):909-17. doi: 10.1007/s00432-007-0351-5

 

 

Journal of Kerman University of Medical Sciences
Volume 32
Pages 1-7

Home

Editorial Board

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us